You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK)在研新藥ALMB-0166獲准在澳大利亞進行臨牀試驗
格隆匯 10-21 18:28

格隆匯10月21日丨石藥集團(01093.HK)宣佈,公司附屬公司AlaMab已獲得相關倫理委員會及臨牀試驗機構批准,並收到政府監管機構(Therapeutic Goods Administration)的臨牀試驗通知確認函,可以在澳大利亞啟動用於治療急性脊髓損傷的在研新藥Connexin 43(Cx43)人源化單克隆抗體(ALMB-0166)首次進入人體的臨牀試驗。

ALMB-0166為針對全新靶點Cx43半通道膜蛋白的同類首創(First-in-class)人源化抗體藥。作為Cx43的抑制劑,ALMB-0166由AlaMab自主研發用於治療急性脊髓損傷,缺血性中風及其它多種臨牀急需的神經性疾病。ALMB-0166於2018年獲得美國FDA頒發用於治療急性脊髓損傷的孤兒藥資格認定。此次臨牀試驗的批准,體現了監管機構對ALMB-0166作為同類首創新藥的臨牀前試驗結果和臨牀試驗可行性的認可。AlaMab並計劃在中國及美國等國家啟動ALMB-0166的相關臨牀研究,以期更快推動該藥物的研發進程。

AlaMab為一家位於美國致力於同類首創抗體藥物開發的創新生物醫藥公司。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account